Zacks Investment Research downgraded shares of Transcat (NASDAQ:TRNS) from a hold rating to a sell rating in a research note released on Wednesday.

According to Zacks, “Transcat, Inc. distributes test and measurement instruments and provides accredited calibration services to a variety of industries including life sciences, pharmaceutical, petroleum refining, chemical manufacturing, public utility, pulp and paper, communications, automotive and aerospace. “

TRNS has been the topic of several other research reports. Singular Research began coverage on shares of Transcat in a research note on Wednesday, November 15th. They set a buy rating and a $15.30 target price on the stock. Dougherty & Co began coverage on shares of Transcat in a research note on Wednesday, August 23rd. They set a buy rating and a $20.00 target price on the stock.

Shares of Transcat (TRNS) traded up $0.08 during midday trading on Wednesday, reaching $13.00. 2,700 shares of the company traded hands, compared to its average volume of 13,159. The stock has a market cap of $92.27, a price-to-earnings ratio of 21.18, a PEG ratio of 3.11 and a beta of 0.47. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.53 and a current ratio of 2.24. Transcat has a 12 month low of $10.30 and a 12 month high of $15.15.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. QCI Asset Management Inc. NY boosted its position in shares of Transcat by 10.0% during the 2nd quarter. QCI Asset Management Inc. NY now owns 24,587 shares of the scientific and technical instruments company’s stock valued at $299,000 after acquiring an additional 2,226 shares during the last quarter. Quantum Capital Management acquired a new position in shares of Transcat during the 3rd quarter valued at about $696,000. Punch & Associates Investment Management Inc. boosted its position in shares of Transcat by 16.8% during the 2nd quarter. Punch & Associates Investment Management Inc. now owns 314,658 shares of the scientific and technical instruments company’s stock valued at $3,823,000 after acquiring an additional 45,308 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in shares of Transcat during the 3rd quarter valued at about $2,484,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Transcat by 3.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 290,146 shares of the scientific and technical instruments company’s stock valued at $3,960,000 after acquiring an additional 8,771 shares during the last quarter. 56.69% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/transcat-trns-lowered-to-sell-at-zacks-investment-research/1776375.html.

Transcat Company Profile

Transcat, Inc is a provider of calibration and laboratory instrument services and a distributor of professional grade test, measurement and control instrumentation. The Company conducts its business through two segments: service (Service) and distribution (Distribution). Through the Service segment, the Company offers calibration, repair, inspection, analytical qualifications, preventative maintenance and other related services, a majority of which are processed through its asset management system, CalTrak (CalTrak).

Receive News & Ratings for Transcat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transcat and related companies with MarketBeat.com's FREE daily email newsletter.